Table3:

Multivariable Regression Analysis Assessing Relationship between Concurrent Carboplatin weekly and Concurrent Cetuximab weekly and patient-reported moderate to severe xerostomia

Variables	Univariate OR	(95% CI)	Univariate P	Multivariable OR	95% CI	Multivariable P	BFDP
Concurrent Carboplatin weekly
No	Ref
Yes	1.82	(1.16–2.85)	0.010	1.66	(1.00–2.75)	0.052	0.916
Concurrent Cetuximab weekly
No	Ref
Yes	0.72	(0.50–1.05)	0.092	0.61	(0.40–0.94)	0.027	0.876

Abbreviations: BFDP, Bayesian false-discovery probabilities

Note:

^*All models controlled for age at diagnosis, RT dose, survival time, sex, race, education, subsite, T-stage, N-stage, HPV, cigarette smoking at diagnosis and survey, solid food diet at baseline, treatment modality, chemotherapy, surgery, neck dissection, RT Schedule, RT Type, and xerostomia during RT.

Statistical significance P ≤ 0.05.

BFDP ≤ 0.8 noteworthy associations.